188 related articles for article (PubMed ID: 38186008)
1. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
4. Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas.
Njølstad TS; Engerud H; Werner HM; Salvesen HB; Trovik J
Gynecol Oncol; 2013 Nov; 131(2):410-5. PubMed ID: 24004646
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.
Ortoft G; Høgdall C; Hansen ES; Dueholm M
Int J Gynecol Cancer; 2021 Aug; 31(8):1116-1124. PubMed ID: 34112735
[TBL] [Abstract][Full Text] [Related]
8. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
9. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.
Zhang Y; Chu R; Zhang Z; Xu C; Liu J; Zhang J; Wang J; Wang Q; Liu C; Feng J; Yao Q; Yao S; Xue F; Guo H; Xia M; Wang X; Zhao W; Li X; Lin B; Zhao X; Ma J; Zhang P; Guo R; Gao Q; Sun C; Ma D; Kong B; Li Y; Chen G; Song K;
Gynecol Oncol; 2023 Sep; 176():43-52. PubMed ID: 37442025
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.
Gorelick C; Andikyan V; Mack M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2009 Nov; 19(8):1384-9. PubMed ID: 20009894
[TBL] [Abstract][Full Text] [Related]
14. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
[TBL] [Abstract][Full Text] [Related]
15. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer.
Holub K; Biete A
BMC Cancer; 2018 Dec; 18(1):1280. PubMed ID: 30577833
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
[TBL] [Abstract][Full Text] [Related]
17. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.
Ren K; Wang W; Sun S; Hou X; Hu K; Zhang F
Cancer Med; 2022 Jan; 11(1):257-267. PubMed ID: 34779587
[TBL] [Abstract][Full Text] [Related]
18. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
19. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
[TBL] [Abstract][Full Text] [Related]
20. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
